---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-043969"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:11:05.767162+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track

## Summary
- Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.
- R&D expenses $19.7M vs $9.2M YoY; G&A expenses $4.1M vs $2.0M YoY; loss from operations $23.8M vs $11.1M YoY.
- Lead program BDC-1001 Phase 1/2 data update expected in 2H 2021; Phase 2 monotherapy and combo dose-escalation to initiate in 2H 2021.
- Announced R&D collaboration with Genmab for bispecific ISACs: $10M upfront + $15M equity investment; Genmab fully funds three programs through initial proof-of-concept.
- Expanded leadership: added VPs in Clinical Development, Early Development, Biometrics, Program Management, HR, and Communications.

## SEC filing metadata
- accession: 0001564590-21-043969
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000156459021043969/0001564590-21-043969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000156459021043969/bolt-8k_20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-043969
- JSON: https://secwatch.observer/filing/0001564590-21-043969.json
- Plain text: https://secwatch.observer/filing/0001564590-21-043969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.